• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

颌骨药物相关性骨坏死的潜在机制

Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw.

作者信息

Lee Kyeongho, Kim Kihun, Kim June Yeon, Kim Jin-Woo, Kang Young-Hoon, Kim Yun Hak, Kim Sung-Jin

机构信息

Department of Oral Histology and Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Korea.

Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan, Korea.

出版信息

Oral Dis. 2025 Apr;31(4):1073-1083. doi: 10.1111/odi.15198. Epub 2024 Nov 18.

DOI:10.1111/odi.15198
PMID:39552606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12022389/
Abstract

OBJECTIVE

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but debilitating disease characterized by a progressive necrosis of jaw bones in patients who have received anti-resorptive or anti-angiogenic therapies. Unfortunately, we still have no validated preventive or pharmaceutical interventions to help these patients, primarily due to our limited understanding of MRONJ pathogenesis. Here, we offer an extensive review of recent studies relevant to MRONJ pathogenesis. We present a hypothesis regarding the coupling of bone resorption and angiogenesis that relies on osteoblast-derived, matrix-bound vascular endothelial growth factors to explain why ONJ is associated with both anti-resorptive and anti-angiogenic agents.

METHODS

A narrative review was conducted by searching databases, including PubMed, Scopus, Google Scholar, and Web of Science, to retrieve relevant reports.

RESULTS

Reduced bone resorption leads to reduced angiogenesis, and vice versa, creating a vicious cycle that ultimately results in ischemic necrosis of the jaw. Additionally, we suggest that reduced angiogenesis, induced by anti-resorptive or anti-angiogenic agents, aggravates bacterial infection-induced bone necrosis, explaining why the jaw bone is particularly susceptible to necrosis.

CONCLUSION

Our novel hypothesis will facilitate the advancement of future research and the development of more targeted approaches to managing MRONJ.

摘要

目的

药物相关性颌骨坏死(MRONJ)是一种罕见但使人衰弱的疾病,其特征为接受抗吸收或抗血管生成治疗的患者颌骨出现进行性坏死。不幸的是,我们仍然没有经过验证的预防或药物干预措施来帮助这些患者,主要原因是我们对MRONJ发病机制的了解有限。在此,我们对近期与MRONJ发病机制相关的研究进行了全面综述。我们提出了一个关于骨吸收与血管生成耦合的假说,该假说依赖于成骨细胞衍生的、与基质结合的血管内皮生长因子,以解释为什么ONJ与抗吸收和抗血管生成药物均有关联。

方法

通过检索包括PubMed、Scopus、谷歌学术和科学网在内的数据库进行叙述性综述,以检索相关报告。

结果

骨吸收减少导致血管生成减少,反之亦然,从而形成恶性循环,最终导致颌骨缺血性坏死。此外,我们认为抗吸收或抗血管生成药物诱导的血管生成减少会加重细菌感染诱导的骨坏死,这解释了为什么颌骨特别容易发生坏死。

结论

我们的新假说将促进未来研究的进展,并推动开发更具针对性的方法来管理MRONJ。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/5a778b679e27/ODI-31-1073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/fe8ec3eb00c1/ODI-31-1073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/670d45aae599/ODI-31-1073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/5a778b679e27/ODI-31-1073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/fe8ec3eb00c1/ODI-31-1073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/670d45aae599/ODI-31-1073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac0/12022389/5a778b679e27/ODI-31-1073-g003.jpg

相似文献

1
Mechanisms Underlying Medication-Related Osteonecrosis of the Jaw.颌骨药物相关性骨坏死的潜在机制
Oral Dis. 2025 Apr;31(4):1073-1083. doi: 10.1111/odi.15198. Epub 2024 Nov 18.
2
Interventions for managing medication-related osteonecrosis of the jaw.颌骨药物相关性骨坏死的管理干预措施。
Cochrane Database Syst Rev. 2017 Oct 6;10(10):CD012432. doi: 10.1002/14651858.CD012432.pub2.
3
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.接受骨靶向治疗患者的颌骨骨坏死:概述——第一部分
Urol Nurs. 2016 May-Jun;36(3):111-6, 154.
4
Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.药物相关性颌骨坏死的诊断与分期
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):479-87. doi: 10.1016/j.coms.2015.06.008. Epub 2015 Aug 18.
5
The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.药物性颌骨坏死的发生率及其相关危险因素。
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9.
6
Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw--2014 update.美国口腔颌面外科医师协会立场文件中的不一致之处:颌骨药物性骨坏死——2014年更新版
J Oral Maxillofac Surg. 2014 Dec;72(12):2381. doi: 10.1016/j.joms.2014.07.045. Epub 2014 Oct 12.
7
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update and CTX.美国口腔颌面外科医师协会关于药物相关性颌骨坏死的立场文件——2014年更新版及CTX
J Oral Maxillofac Surg. 2015 Mar;73(3):377. doi: 10.1016/j.joms.2014.10.035.
8
Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.抗血管生成药物通过损害牙龈成纤维细胞的增殖和迁移功能,加重了基于抗吸收药物的药物相关性颌骨坏死的程度。
BMC Oral Health. 2023 May 27;23(1):330. doi: 10.1186/s12903-023-03034-7.
9
American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.美国口腔颌面外科医师协会关于药物相关性颌骨坏死的立场文件——2014年更新版
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5.
10
The role of illicit drugs in developing medication-related osteonecrosis (MRONJ): a systematic review.非法药物在导致药物相关性骨坏死(MRONJ)中的作用:系统评价。
Br J Oral Maxillofac Surg. 2021 May;59(4):398-406. doi: 10.1016/j.bjoms.2020.08.079. Epub 2020 Aug 20.

引用本文的文献

1
Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review.已确定的导致药物相关性颌骨坏死的药物:文献综述
Cureus. 2025 Jun 24;17(6):e86645. doi: 10.7759/cureus.86645. eCollection 2025 Jun.

本文引用的文献

1
Current Knowledge on the Healing of the Extraction Socket: A Narrative Review.拔牙创愈合的当前知识:一项叙述性综述
Bioengineering (Basel). 2023 Sep 29;10(10):1145. doi: 10.3390/bioengineering10101145.
2
Identification of Potential Biomarkers and Small Molecule Drugs for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): An Integrated Bioinformatics Study Using Big Data.基于大数据的整合生物信息学研究:鉴定双膦酸盐相关性颌骨骨坏死(BRONJ)的潜在生物标志物和小分子药物
Int J Mol Sci. 2023 May 11;24(10):8635. doi: 10.3390/ijms24108635.
3
Obesity and periodontitis: A systematic review and updated meta-analysis.
肥胖与牙周炎:系统评价与更新的荟萃分析。
Front Endocrinol (Lausanne). 2022 Oct 24;13:999455. doi: 10.3389/fendo.2022.999455. eCollection 2022.
4
Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.基于美国食品药品监督管理局不良事件报告系统数据库的抗吸收相关颌骨坏死真实世界研究
Front Pharmacol. 2022 Oct 19;13:1017391. doi: 10.3389/fphar.2022.1017391. eCollection 2022.
5
Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ).建立和评估与药物相关的颌骨坏死(MRONJ)的啮齿动物模型。
Int J Oral Sci. 2022 Aug 10;14(1):41. doi: 10.1038/s41368-022-00182-4.
6
Association between periodontal disease, tooth extraction, and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study.接受双膦酸盐治疗的女性中,牙周疾病、拔牙与药物相关颌骨坏死之间的关联:一项基于全国队列的研究。
J Periodontol. 2023 Jan;94(1):98-107. doi: 10.1002/JPER.21-0611. Epub 2022 Aug 12.
7
American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update.美国口腔颌面外科学会关于药物相关性颌骨坏死的立场文件-2022 更新。
J Oral Maxillofac Surg. 2022 May;80(5):920-943. doi: 10.1016/j.joms.2022.02.008. Epub 2022 Feb 21.
8
Skeletal infections: microbial pathogenesis, immunity and clinical management.骨骼感染:微生物发病机制、免疫与临床管理。
Nat Rev Microbiol. 2022 Jul;20(7):385-400. doi: 10.1038/s41579-022-00686-0. Epub 2022 Feb 15.
9
Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.颌骨骨坏死与良性及恶性疾病中的抗吸收药物:由 ECTS 组织的批判性回顾。
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: 10.1210/clinem/dgab888.
10
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.唑来膦酸与地舒单抗治疗骨质疏松症患者颌骨坏死的风险比较。
J Bone Miner Res. 2022 Feb;37(2):340-348. doi: 10.1002/jbmr.4472. Epub 2021 Nov 30.